DEENOVA
20.10.2021 06:02:05 CEST | Business Wire | Press release
Deenova announced today it continues its record-breaking market momentum started during Covid-19 , by winning 2 mechatronic competitive public tenders this Summer for a total of 4 ACCED robotic medication solutions to be operated around the clock at Centre Hospitalier Sainte-Marie Rodez in Occitanie, and Hospital of St Die-des-Vosges near Strasburg.
Loïc Bessin , Managing Director of Deenova in France stated: “When I joined Deenova 3 years ago, the company was a small unit dose specialty business only present in 2 of the Top 5 European markets, having had customers only in France and Italy. I am extremely proud that over the last year alone, we have grown to become the dominant force in the GDP Top 5 healthcare European mechatronics markets for unit-dose, by establishing close partnership with key customers.”
Christophe Jaffuel , Deenova Chief Commercial Officer, stated: “After Deenova multi-million and multi-year recent entries into the two largest European GDP healthcare markets in Germany and the United Kingdom, it is very reassuring to see the continued market success in one of our established countries such as France. Both in terms of total number of customers and number of mechatronic devices, I am very proud that France continues to pave the way for Deenova ´s international growth for 2 consecutive years and counting, highlighting Deenova main differentiating characteristics over our competition in France: patient care crafted for compliance, better safety and therapy control, and 24/7 availability, a key component of customer needs”.
Centre Hospitalier Sainte-Marie Rodez in Occitanie takes care of people with mental illness in Aveyron (4 out of 5 psychiatric sectors) and has 311 beds and complete hospital places (CHSM Rodez, Clinique de Bourran and Clinique de Villefranche-sur-Rouergue) and 115 partial hospitalization beds.
Hospital of St Die-des-Vosges . A benchmark establishment in a hospital community serving a population of 90,000 inhabitants, the Hospital of St Die-des-Vosges constantly strives to improve the quality of care provided to patients. The hospital is committed to carrying out common orientations and activities between the establishments in order to optimise the care and health coverage of the inhabitants of the territory of the Deodatie, serving the community with 452 beds.
Deenova
is the undisputed leading supplier of combined mechatronics (robotic and automation)
solutions for closed loop medications and RFID-based medical devices traceability in the healthcare industry, anytime and anywhere. Deenova’s unique, patented, and fully integrated solutions have and will greatly contribute to ease healthcare providers’ growing pressures to: simultaneously improve patient safety, reduce therapy errors, minimise waste and controlled substance diversion, contain costs, and diminish the gap between rising patient volume/acuity and scarce medical staff. Deenova guarantees the simplification of all processes related to the management of medications and implantable/disposable medical devices with an expected cost savings range between 15% and 25%.
Please visit www.deenova.com
for additional information on its market leading solutions.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211019005648/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Together AI and HUMAIN Form Strategic Partnership to Accelerate AI Infrastructure and Cloud Services in Saudi Arabia31.8.2026 14:00:00 CEST | Press release
The partnership, which was announced on stage at LEAP, Combines HUMAIN’s AI Infrastructure Foundation with Together’s AI Native Cloud Platform and Global Reach Together AI, a leading San Francisco-based AI Native Cloud platform, and HUMAIN, a PIF company delivering full-stack artificial intelligence capabilities globally, today at LEAP announced a strategic partnership to connect HUMAIN’s rapidly expanding AI compute capacity in Saudi Arabia with global AI-native and enterprise demand. The partnership will include the construction of a new 250 megawatt data center, located in Saudi Arabia. The partnership brings together HUMAIN’s large-scale, multi-chip AI infrastructure footprint, expanding cloud and inference capabilities with Together AI’s global customer ecosystem and AI-native inference platform. Together, the companies will offer an additional option for developers, enterprises, and AI-native organizations worldwide to access high-performance AI infrastructure for inference and t
SLB to Acquire Kelvion, Expanding its Role Across Data Center Infrastructure31.8.2026 12:50:00 CEST | Press release
Scalable, energy-efficient and reliable thermal management technologies will optimize operating performance in increasingly complex data centers and industrial systems SLB (NYSE: SLB) today announced it has signed an agreement to acquire Kelvion, a global provider of thermal management and heat exchange technologies. The acquisition strengthens SLB's Data Center Solutions business with critical thermal management technologies and expands the company's role in data center infrastructure, which is one of the world’s fastest-growing industrial and technology markets. “AI is driving the most significant infrastructure investment cycle in our lifetime,” said Olivier Le Peuch, chief executive officer of SLB. “This transaction accelerates our ambition to become an industrial technology partner to the data center industry and help customers address the growing infrastructure complexity required to scale AI. Kelvion advances our path toward more integrated data center infrastructure solutions,
BeOne Medicines Announces New Phase 3 Survival Data Reinforcing Benefit of ZIIHERA-Containing Regimens in First-Line HER2+ Gastroesophageal Cancer31.8.2026 12:00:00 CEST | Press release
Findings provide further evidence of overall survival benefit of TEVIMBRA plus ZIIHERA and chemotherapy regimen in HER2+ GEAZIIHERA plus chemotherapy demonstrated statistically significant overall survival benefit at second interim analysis of HERIZON-GEA-01 trial BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced positive topline results from the second interim analysis (IA2) of the Phase 3 HERIZON-GEA-01 trial evaluating ZIIHERA® (zanidatamab), in combination with chemotherapy, with and without TEVIMBRA® (tislelizumab), as first-line treatment for HER2+ locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). At IA2, ZIIHERA plus chemotherapy demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS) compared with trastuzumab plus chemotherapy, meeting the remaining primary endpoint analysis of the study. IA2 also provided longer follow-up data for the TEVIMBRA plus ZIIHERA
GigaDevice Strengthens EMEA and Southeast Asia Market Reach Through Strategic Partnership with Rutronik31.8.2026 09:00:00 CEST | Press release
GigaDevice, a leading semiconductor company specializing in Flash memory, 32-bit microcontrollers (MCUs), sensors, and analog products, today announced a new strategic franchise partnership with Rutronik Elektronische Bauelemente GmbH, one of Europe’s leading broadline distributors of electronic components. The agreement covers EMEA and Southeast Asia, including India, and provides customers with broader access to GigaDevice’s comprehensive portfolio of microcontrollers, sensors, and power management solutions. The partnership further strengthens GigaDevice’s distribution network and local market presence across key regions. With its strong presence across Europe and growing coverage in Southeast Asia, Rutronik provides GigaDevice with an established channel supported by extensive market reach, technical expertise, and customer relationships. The collaboration will help expand access to GigaDevice’s embedded solutions across a broad range of applications and industries, including indus
Alnylam Presents New Data at ESC Congress 2026 Reinforcing Strength in RNAi-Powered TTR Silencing Across ATTR-CM Patient Populations and Treatment Settings30.8.2026 14:23:00 CEST | Press release
–Late-Breaking Prespecified Subgroup Analysis of HELIOS-B Demonstrates that Vutrisiran Provided Consistent Clinical Benefit Across All-Cause Mortality and Recurrent Cardiovascular Events in Patients With or Without Tafamidis Use at Baseline ––Additional Post Hoc Analyses Highlight Positive Impact of Vutrisiran in Addressing the Multisystemic Manifestations of ATTR-CM ––Pooled Analysis Across Four Positive Phase 3 Studies of Vutrisiran and Patisiran Shows Consistent Treatment Effect Across Sexes ––New Subgroup Analysis from KARDIA-3 Phase 2 Study of Zilebesiran Highlights Potential to Provide Enhanced Blood Pressure Control – Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new data at the European Society of Cardiology (ESC) Congress 2026 demonstrating the strength of RNAi-powered silencing for cardiovascular disease. The findings further reinforce the clinical profile of AMVUTTRA® (vutrisiran) across transthyretin amyloidosis (ATTR)
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom